prikaz prve stranice dokumenta Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
  Download
PDF 412.63 KB
Scientific paper - Original scientific paper
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
Croatian medical journal, 62 (2021), 5; 455-463. https://doi.org/10.3325/cmj.2021.62.455-63
Bašić-Kinda, Sandra; Mišura Jakobac, Karla; Sinčić-Petričević, Jasminka; Deak, Dajana; Vodanović, Marijo; Jakić-Bubalo, Marinka; Mitrović, Zdravko; Grubešić, Aron; Dreta, Barbara; Županić Krmek, Dubravka; Coha, Božena; Radić-Krišto, Delfa; Aurer, Igor

Cite this document

Bašić Kinda, S., Mišura Jakobac, K., Sinčić Petričević, J., Deak, D., Vodanović, M., Jakić Bubalo, M. ... Aurer, I. (2021). Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases. Croatian medical journal, 62. (5), 455-463. doi: 10.3325/cmj.2021.62.455-63

Bašić Kinda, Sandra, et al. "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases." Croatian medical journal, vol. 62, no. 5, 2021, pp. 455-463. https://doi.org/10.3325/cmj.2021.62.455-63

Bašić Kinda, Sandra, Karla Mišura Jakobac, Jasminka Sinčić Petričević, Dajana Deak, Marijo Vodanović, Marinka Jakić Bubalo, Zdravko Mitrović, et al. "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases." Croatian medical journal 62, no. 5 (2021): 455-463. https://doi.org/10.3325/cmj.2021.62.455-63

Bašić Kinda, S., et al. (2021) 'Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases', Croatian medical journal, 62(5), pp. 455-463. doi: 10.3325/cmj.2021.62.455-63

Bašić Kinda S, Mišura Jakobac K, Sinčić Petričević J, Deak D, Vodanović M, Jakić Bubalo M, and sur.. Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases. Croatian medical journal [Internet]. 2021 [cited 2024 November 12];62(5):455-463. doi: 10.3325/cmj.2021.62.455-63

S. Bašić Kinda, et al., "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases", Croatian medical journal, vol. 62, no. 5, pp. 455-463, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:936669. [Accessed: 12 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
AuthorSandra Bašić-Kinda
AuthorKarla Mišura Jakobac
AuthorJasminka Sinčić-Petričević
AuthorDajana Deak
AuthorMarijo Vodanović
AuthorMarinka Jakić-Bubalo
AuthorZdravko Mitrović
MBZ: 272370
AuthorAron Grubešić
AuthorBarbara Dreta
AuthorDubravka Županić Krmek
MBZ: 228753
AuthorBožena Coha
MBZ: 234601
AuthorDelfa Radić-Krišto
MBZ: 243612
AuthorIgor Aurer
MBZ: 165536
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Aim To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). Methods The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units. Demographic characteristics and data on induction regimens, autologous stem cell transplantation (ASCT), and rituximab maintenance in the first remission, event-free survival (EFS), and overall survival (OS) were available for both cohorts, and data on cell morphology, mantle cell international prognostic index (MIPI), and Ki67 expression only for the recent cohort. Results The recent cohort had significantly better two-year EFS and OS (EFS 58% vs 40%, P = 0.014 ; OS 80% vs 56%, P = 0.009), especially in patients below 65. In univariate analysis, induction regimen, ASCT, and maintenance were significant prognostic factors for EFS and the former two for OS. In the multivariate analysis, only ASCT remained significant. Bendamustine + rituximab (BR) induction improved the outcomes of non- transplantable patients over R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, steroid). Blastoid morphology and high MIPI were adverse prognostic factors for EFS and OS. Conclusion In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non- transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian medical journal
Numberingvol. 62, no. 5, pp. 455-463
p-ISSN0353-9504
DOIhttps://doi.org/10.3325/cmj.2021.62.455-63
URN:NBNurn:nbn:hr:184:936669
Publication2021
Document URLhttp://bib.irb.hr/1193971
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) icon
Created on2023-02-02 08:03:43